68Ga-PSMA PET/CT Uptake in the Ureter Caused by Ligand Expression in Urothelial Cancer.
Aged
Antigens, Surface
/ metabolism
Biological Transport
Gallium Isotopes
Gallium Radioisotopes
Gene Expression Regulation, Neoplastic
Glutamate Carboxypeptidase II
/ metabolism
Humans
Ligands
Male
Membrane Glycoproteins
/ metabolism
Organometallic Compounds
/ metabolism
Positron Emission Tomography Computed Tomography
Prostatectomy
Prostatic Neoplasms
/ diagnostic imaging
Recurrence
Ureter
/ metabolism
Urologic Neoplasms
/ diagnostic imaging
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
pubmed:
16
7
2019
medline:
23
2
2020
entrez:
16
7
2019
Statut:
ppublish
Résumé
Ga-PSMA PET/CT has become a well-established imaging modality to detect prostate cancer (PCa) metastases in biochemical recurrence. Despite its claimed specificity for PCa, Ga-PSMA uptake in tissues unrelated to PCa, particularly in the neovascular tissue of other cancers, has been reported in numerous studies. A 73-year-old man underwent Ga-PSMA PET/CT for biochemical recurrence of PCa 7 years after radical prostatectomy. The Ga-PSMA PET/CT showed 1 lesion with PSMA uptake in the distal left ureter. Histology revealed a low-grade noninvasive papillary urothelial carcinoma. By immunohistochemistry, PSMA expression was observed in the neoplastic urothelial cells and in the vessels of the papillary structures.
Identifiants
pubmed: 31306199
doi: 10.1097/RLU.0000000000002720
pii: 00003072-202001000-00036
doi:
Substances chimiques
Antigens, Surface
0
Gallium Isotopes
0
Gallium Radioisotopes
0
Ligands
0
Membrane Glycoproteins
0
Organometallic Compounds
0
gallium 68 PSMA-11
0
FOLH1 protein, human
EC 3.4.17.21
Glutamate Carboxypeptidase II
EC 3.4.17.21
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e43-e45Références
Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630–642.
van Leeuwen PJ, Stricker P, Hruby G, et al. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int. 2016;117:732–739.
Afshar-Oromieh A, Holland-Letz T, Giesel FL, et al. Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44:1258–1268.
Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019.
Rowe SP, Gorin MA, Hammers HJ, et al. Detection of 18F-FDG PET/CT occult lesions with 18F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma. Clin Nucl Med. 2016;41:83–85.
Zacho HD, Nielsen JB, Dettmann K, et al. Incidental detection of thyroid metastases from renal cell carcinoma using 68Ga-PSMA PET/CT to assess prostate cancer recurrence. Clin Nucl Med. 2017;42:221–222.
Gupta M, Choudhury PS, Gupta G, et al. Metastasis in urothelial carcinoma mimicking prostate cancer metastasis in Ga-68 prostate-specific membrane antigen positron emission tomography-computed tomography in a case of synchronous malignancy. Indian J Nucl Med. 2016;31:222–224.
Campbell SP, Baras AS, Ball MW, et al. Low levels of PSMA expression limit the utility of (18)F-DCFPyL PET/CT for imaging urothelial carcinoma. Ann Nucl Med. 2018;32:69–74.
Heitkotter B, Trautmann M, Grunewald I, et al. Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST. Oncotarget. 2016;8:4268–4276.
Gykiere P, Goethals L, Everaert H. Healing sacral fracture masquerading as metastatic bone disease on a 68Ga-PSMA PET/CT. Clin Nucl Med. 2016;41:e346–e347.
Sasikumar A, Joy A, Nanabala R, et al. 68Ga-PSMA PET/CT false-positive tracer uptake in Paget disease. Clin Nucl Med. 2016;41:e454–e455.
Zacho HD, Nielsen JB, Dettmann K, et al. 68Ga-PSMA PET/CT uptake in intramuscular myxoma imitates prostate cancer metastasis. Clin Nucl Med. 2017;42:487–488.
Vamadevan S, Shetty D, Le K, et al. Prostate-specific membrane antigen (PSMA) avid pancreatic neuroendocrine tumor. Clin Nucl Med. 2016;41:804–806.